Endometriosis is a chronic inflammatory disease characterised by pain, infertility and recurrence. Current pharmacological management relies largely on hormonal suppression, which can reduce pain and disease activity but does not …
Endometriosis is a chronic inflammatory and sex steroid hormone-dependent gynaecologic disease, characterised by endometrial cell proliferation outside the uterine cavity, often accompanied by fibrosis, progesterone resistance, and high recurrence despite …
In this narrative review, we summarize current evidence regarding the endometrium undergoes cyclic remodeling driven by estrogen (E2) and progesterone (P4) signaling, with precise coordination essential for receptivity and pregnancy …
Endometriosis (EMs) is a chronic neuroinflammatory disorder prevalent in women of reproductive age characterized by heterogeneous clinical manifestations, while conventional Western therapies are limited by obvious adverse reactions and unsatisfactory …
Endocrine-disrupting chemicals (EDCs) are ubiquitous environmental contaminants that interfere with hormone signalling and are increasingly linked to adverse reproductive outcomes. This viewpoint highlights emerging evidence that EDC exposure disrupts both …
Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …
Endometriosis is an estrogen-dependent disorder characterized by chronic inflammation, immune dysregulation, and altered hormone metabolism. Although gut microbiota-derived metabolites have been implicated in shaping immune microenvironments and lesion development, the …
Endometriosis is a chronic inflammatory disorder lacking definitive laboratory diagnostic markers. Angiopoietin-like protein-4 (ANGPTL4) is a protein involved in the regulation of angiogenesis and inflammation. The aim of the present …
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
This study aimed to investigate the factors affecting the decline of serum anti-Müllerian hormone (AMH) in reproductive-aged women following minimally invasive ovarian cystectomy. A retrospective cohort study was conducted using …